Cargando…

Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial

BACKGROUND: Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection. With this approach, local control ranges between 50% and 70%, depending on resection status. A series or smaller studies has shown that postoperative radiotherapy in this patient population...

Descripción completa

Detalles Bibliográficos
Autores principales: Combs, Stephanie E, Edler, Lutz, Burkholder, Iris, Rieken, Stefan, Habermehl, Daniel, Jäkel, Oliver, Haberer, Thomas, Unterberg, Andreas, Wick, Wolfgang, Debus, Jürgen, Haselmann, Renate
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996393/
https://www.ncbi.nlm.nih.gov/pubmed/21062428
http://dx.doi.org/10.1186/1471-2407-10-615
_version_ 1782193199970779136
author Combs, Stephanie E
Edler, Lutz
Burkholder, Iris
Rieken, Stefan
Habermehl, Daniel
Jäkel, Oliver
Haberer, Thomas
Unterberg, Andreas
Wick, Wolfgang
Debus, Jürgen
Haselmann, Renate
author_facet Combs, Stephanie E
Edler, Lutz
Burkholder, Iris
Rieken, Stefan
Habermehl, Daniel
Jäkel, Oliver
Haberer, Thomas
Unterberg, Andreas
Wick, Wolfgang
Debus, Jürgen
Haselmann, Renate
author_sort Combs, Stephanie E
collection PubMed
description BACKGROUND: Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection. With this approach, local control ranges between 50% and 70%, depending on resection status. A series or smaller studies has shown that postoperative radiotherapy in this patient population can increase progression-free survival, which translates into increased overall survival. However, meningiomas are known to be radioresistant tumors, and radiation doses of 60 Gy or higher have been shown to be necessary for tumor control. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed. First data obtained within the Phase I/II trial performed at GSI in Darmstadt on carbon ion radiotherapy for patients with high-risk meningiomas has shown safety, and treatment results are promising. METHODS/DESIGN: The Phase II-MARCIE-Study will evaluate a carbon ion boost applied to the macroscopic tumor in conjunction with photon radiotherapy in patients with atypical menigiomas after incomplete resection or biopsy. Primary endpoint is progression-free survival, secondary endpoints are overall survival, safety and toxicity. DISCUSSION: Based on published data on the treatment of atypical meningiomas with carbon ions at GSI, the present study will evaluate this treatment concept in a larger patient population and will compare outcome to current standard photon treatment. TRIAL REGISTRATION: NCT01166321
format Text
id pubmed-2996393
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29963932010-12-03 Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial Combs, Stephanie E Edler, Lutz Burkholder, Iris Rieken, Stefan Habermehl, Daniel Jäkel, Oliver Haberer, Thomas Unterberg, Andreas Wick, Wolfgang Debus, Jürgen Haselmann, Renate BMC Cancer Study Protocol BACKGROUND: Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection. With this approach, local control ranges between 50% and 70%, depending on resection status. A series or smaller studies has shown that postoperative radiotherapy in this patient population can increase progression-free survival, which translates into increased overall survival. However, meningiomas are known to be radioresistant tumors, and radiation doses of 60 Gy or higher have been shown to be necessary for tumor control. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed. First data obtained within the Phase I/II trial performed at GSI in Darmstadt on carbon ion radiotherapy for patients with high-risk meningiomas has shown safety, and treatment results are promising. METHODS/DESIGN: The Phase II-MARCIE-Study will evaluate a carbon ion boost applied to the macroscopic tumor in conjunction with photon radiotherapy in patients with atypical menigiomas after incomplete resection or biopsy. Primary endpoint is progression-free survival, secondary endpoints are overall survival, safety and toxicity. DISCUSSION: Based on published data on the treatment of atypical meningiomas with carbon ions at GSI, the present study will evaluate this treatment concept in a larger patient population and will compare outcome to current standard photon treatment. TRIAL REGISTRATION: NCT01166321 BioMed Central 2010-11-09 /pmc/articles/PMC2996393/ /pubmed/21062428 http://dx.doi.org/10.1186/1471-2407-10-615 Text en Copyright ©2010 Combs et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Combs, Stephanie E
Edler, Lutz
Burkholder, Iris
Rieken, Stefan
Habermehl, Daniel
Jäkel, Oliver
Haberer, Thomas
Unterberg, Andreas
Wick, Wolfgang
Debus, Jürgen
Haselmann, Renate
Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial
title Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial
title_full Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial
title_fullStr Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial
title_full_unstemmed Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial
title_short Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial
title_sort treatment of patients with atypical meningiomas simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the marcie trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996393/
https://www.ncbi.nlm.nih.gov/pubmed/21062428
http://dx.doi.org/10.1186/1471-2407-10-615
work_keys_str_mv AT combsstephaniee treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT edlerlutz treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT burkholderiris treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT riekenstefan treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT habermehldaniel treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT jakeloliver treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT habererthomas treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT unterbergandreas treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT wickwolfgang treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT debusjurgen treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial
AT haselmannrenate treatmentofpatientswithatypicalmeningiomassimpsongrade4and5withacarbonionboostincombinationwithpostoperativephotonradiotherapythemarcietrial